Article

Treatment of postnasal drip with proton pump inhibitors: A prospective, randomized, placebo-controlled study

Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA.
American Journal of Rhinology (Impact Factor: 1.36). 11/2007; 21(6):695-701. DOI: 10.2500/ajr.2007.21.3098
Source: PubMed

ABSTRACT Patients commonly present with complaints of postnasal drainage (PND) without objective evidence to support a sinonasal or infectious etiology. PND has been attributed to extra-esophageal reflux (EER), and an empiric trial of antireflux medication often is used to treat PND and associated symptoms. This study was performed to (1) evaluate the relationship between symptoms of EER and PND and (2) assess the efficacy of proton pump inhibitors (PPIs) in the management of PND.
Patients with a chief complaint of PND without objective evidence of sinonasal inflammatory disease were enrolled in a prospective, double-blinded, randomized placebo-controlled trial using rabeprazole, 20 mg, orally twice daily or placebo for 90 days. Subjects completed two-site 24-hour pharyngeal pH probe monitoring before treatment. Outcome measures included pre- and posttreatment visual analog scales for PND symptoms, reflux symptom index, and reflux finding score (RFS).
Forty-seven patients were enrolled (mean age, 55 years)-21 patients in the PPI group and 26 in the placebo group. Fifty-six percent of subjects had pH probe confirmed EER using a cutoff of pH < 5.0. Baseline symptom measures between subjects with and without EER were not different. Compared with placebo, subjects receiving rabeprazole reported significant reduction in PND frequency (p = 0.0180), hoarseness (p = 0.0164), and chronic cough (p = 0.0204). The RFS decreased slightly in the placebo group (p = 0.1490) whereas it increased slightly in the PPI group (p = 0.5235). This difference between groups was significant (p = 0.0272).
Although 50% of subjects had evidence of EER, there was no difference in baseline symptoms between subjects with and without. Our findings support the potential benefit of PPI therapy for reducing PND frequency, hoarseness, and chronic cough, and confirm a placebo effect for other laryngopharyngeal reflux symptoms. The effect on laryngeal findings is mixed and patients may experience symptomatic improvement before changes in laryngoscopic appearance.

1 Follower
 · 
180 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Supraesophageal reflux disease (SERD), defined as reflux proximal to the upper esophageal sphincter, is a common cause of morbidity of the upper aerodigestive tract, including rhinitis, laryngitis, cough, postnasal drip, and throat clearing. Although SERD has a high prevalence, the ideal means of diagnosing and treating the disease remain poorly defined. Evolving pH monitoring technology and a body of literature with conflicting reports regarding the best means for measuring and interpreting supraesophageal acidic reflux complicates the diagnosis of SERD. Treatment options include empiric acid suppression therapy, lifestyle modification, and surgery. However, limited data regarding the effectiveness of these strategies vary between studies and patient populations. It is the goal of this article to summarize the presentation and pathogenesis of SERD and to integrate the evolving body of literature pertaining to diagnostic and treatment strategies.
    Allergy and Asthma Proceedings 03/2014; 35(2):104-10. DOI:10.2500/aap.2014.35.3719 · 3.35 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This article reviews the evaluation and management of patients with suspected extraesophageal manifestations of gastroesophageal reflux disease, such as asthma, chronic cough, and laryngitis, which are commonly encountered in gastroenterology practices. Otolaryngologists and gastroenterologists commonly disagree upon the underlying cause for complaints in patients with one of the suspected extraesophageal reflux syndromes. The accuracy of diagnostic tests (laryngoscopy, endoscopy, and pH- or pH-impedance monitoring) for patients with suspected extraesophageal manifestations of gastroesophageal reflux disease is suboptimal. An empiric trial of proton pump inhibitors in patients without alarm features can help some patients, but the response to therapy is variable.
    Gastroenterology clinics of North America 03/2014; 43(1):105-120. DOI:10.1016/j.gtc.2013.11.007 · 1.92 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: ZusammenfassungDie gastroösophageale Refluxkrankheit zählt zu den häufigsten internistischen Krankheitsbildern. Die möglichen klinischen Manifestationen betreffen sowohl ösophageale als auch extraösophageale Symptome. Etablierte extraösophageale Assoziationen sind Refluxhusten, Refluxlaryngitis, Refluxasthma, dentale Erosionen und Schlafstörungen. Bei fehlendem diagnostischem Goldstandard beschränkt sich die Diagnostik häufig in der probatorisch hoch dosierten und lang genug durchgeführten Therapie mit Protonenpumpenblockern (PPI). Die in den letzten Jahren durchgeführten kontrollierten Studien zeigen, dass sich extraösophageale Symptome häufig nur dann bessern, wenn gleichzeitig eine Refluxkrankheit mit typischen Symptomen vorliegt. Bestehen keine Refluxsymptome, ist eine dem extraösophagealen Symptom zugrunde liegende Refluxgenese unwahrscheinlich und somit eine probatorische PPI-Therapie nur in Ausnahmefällen sinnvoll.
    Viszeralmedizin / Visceral Medicine 01/2011; 27:146-151. DOI:10.1159/000326916 · 0.10 Impact Factor